Palvella Therapeutics (NASDAQ:PVLA) Issues Earnings Results

Palvella Therapeutics (NASDAQ:PVLA) released its quarterly earnings data on Thursday. The company reported ($1.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.78) by $0.08, FiscalAI reports.

Here are the key takeaways from Palvella Therapeutics’ conference call:

• Positive sentiment: The FDA accepted Palvella’s QTORIN rapamycin NDA for microcystic lymphatic malformations and granted Priority Review, setting a February 28, 2027 PDUFA date. If approved, it would be the first FDA-approved treatment for the condition.
• Positive sentiment: Management cited physician research showing more than 70% of surveyed doctors expect to prescribe QTORIN rapamycin within three months of approval. The company estimates more than 30,000 diagnosed U.S. patients and says the opportunity could exceed $1 billion in peak annual U.S. sales; these are company estimates, not established results.
• Positive sentiment: Palvella said it is preparing a roughly 70-person commercial and medical team for a potential launch, including about 40 frontline sales representatives. Payer discussions have been constructive, though coverage and access remain to be established.
• Positive sentiment: The company plans to start a Phase III study of QTORIN rapamycin for cutaneous venous malformations this quarter and expects Phase II results for angiokeratomas in the second half of 2027. It also reported continued development progress for its DSAP candidate, extending its pipeline beyond the lead program.
• Negative sentiment: Palvella ended Q3 with $236.7 million in cash and said it expects funding to last deep into a potential launch, but anticipates its largest investment to date in Q4 as hiring and pre-commercial spending increase. Management cautioned that early revenue may lag demand while payer coverage, treatment-center workflows, and patient access processes are established, and it will not provide specific 2027 revenue guidance.

Palvella Therapeutics Stock Performance

Shares of PVLA traded up $19.07 during mid-day trading on Friday, hitting $175.92. 502,014 shares of the stock were exchanged, compared to its average volume of 237,190. The company has a market cap of $2.54 billion, a PE ratio of -31.99 and a beta of -0.21. Palvella Therapeutics has a 52-week low of $72.22 and a 52-week high of $176.94. The firm has a 50-day moving average of $142.54 and a two-hundred day moving average of $128.12.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on PVLA shares. Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. HC Wainwright assumed coverage on shares of Palvella Therapeutics in a report on Friday. They issued a “strong-buy” rating on the stock. Raymond James Financial set a $226.00 price target on shares of Palvella Therapeutics in a research note on Friday, October 16th. Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $213.00.

Insider Activity at Palvella Therapeutics

In related news, Director Christopher Kiritsy sold 313 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total value of $49,141.00. Following the sale, the director owned 250 shares in the company, valued at approximately $39,250. The trade was a 55.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director George Jenkins sold 13,352 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $151.96, for a total transaction of $2,028,969.92. Following the sale, the director directly owned 161,893 shares in the company, valued at approximately $24,601,260.28. The trade was a 7.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 61,056 shares of company stock valued at $8,756,946. 17.20% of the stock is owned by corporate insiders.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.